NovaBridge Biosciences (NBP) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 11 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for NBP is $9.00, representing a +246.2% upside from the current price of $2.6. Price targets range from a low of $9.00 to a high of $9.00.
